Pancreatic carcinoma in a ten-year survivor of acute myeloblastic leukemia.
Adenocarcinoma of the pancreas developed in a young man who was a 10-year survivor of acute myeloblastic leukemia (AML). His extensive cytotoxic chemotherapy for AML is reviewed along with a discussion of its possible oncogenic effects. Other case reports of second malignant neoplasms (SMN) following acute leukemia are cited; available data suggest that the overall risk of SMN in AML may be in the range of 6%. While our patient's second malignancy may have been a chance association, his and other cases of pancreatic carcinoma in young survivors of hematologic neoplasia suggest that the cytotoxic treatment may have had a role in the pathogenesis of the pancreatic carcinoma.
D000230:Adenocarcinoma / Q000209:etiology* / Q000556:secondary; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001853:Bone Marrow / Q000473:pathology; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D010190:Pancreatic Neoplasms / Q000209:etiology* / Q000473:pathology / Q000556:secondary; D012306:Risk
D000970:Antineoplastic Agents